05:38 AM EST, 11/13/2026 (MT Newswires) -- NFL Biosciences (ALNFL.PA) filed a new patent request to extend the protection for NFL-102, an immunotherapy for the treatment of tobacco dependence, into new therapeutic applications. The extension focuses on neurotransmitters that impact tobacco and nicotine dependence, according to a Friday release. The biopharmaceutical company expects the patent to run until 2047, excluding potential regulatory extensions, if approved. NFL Biosciences added that the new filing expands its existing intellectual property portfolio of five complementary patent families.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.